Beacon-Neuro.AI Inc., a Washington University in St. Louis startup, has received FDA Breakthrough Device designation for BeaconPredict, an artificial intelligence (AI)-powered software platform designed to predict malignant cerebral oedema following acute stroke.
The technology aims to help clinicians identify patients at high risk of severe brain swelling before symptoms become critical, enabling earlier intervention and improved treatment decisions.
Malignant cerebral oedema is a life-threatening stroke complication that can lead to significant mortality if not managed quickly.
BeaconPredict analyses brain imaging data collected within the first 24 hours of hospital admission, combined with clinical information such as blood pressure, age and neurological examination results, to generate an individualised risk assessment.
In a study involving 598 stroke patients from three medical centres, the AI system demonstrated 99% accuracy in identifying patients who may require surgery to relieve pressure caused by brain swelling.
The platform also achieved an 87% precision rate in identifying patients needing intervention, outperforming traditional assessment approaches.
Developed by researchers at WashU Medicine, BeaconPredict is being advanced by Beacon-Neuro.AI, which was co-founded by neurology and radiology experts from the institution.
The FDA Breakthrough Device designation provides an accelerated regulatory pathway and additional support to help bring innovative stroke care technology closer to clinical use.
